Osborne Clarke advises iOnctura on its EUR 80 Million Series B Financing
Osborne Clarke has advised iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, on its EUR80 million Series...
Published on
24/06/2024
Read time
1m